drugset / Trial / NCT04522544
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
Phase 2
Active not recruiting
55 enrolled
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
AstraZeneca · collabHannover Medical School · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A Phase II study of immunotherapy with Durvalumab (MEDI4736) and Tremelimumab in combination with Y-90 SIRT for intermediate stage HCC
Timeline
- Start
- 2020-12-15
- Primary completion
- 2027-07-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | — |
| Subject | Tremelimumab | Monoclonal antibody | 300 mg | — |